Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Tomas Jose Gonzalez-Lopez, Nuria Bermejo, Rocío Cardesa-Cabrera, Violeta Martínez, Gerardo Aguilar-Monserrate, Gloria Pérez Segura, Abel Domingo García, Josefa Luis-Navarro, Sunil Lakhwani, Natalia Acedo, Maria L Lozano, Silvia Bernat, Ana Torres-Tienza, Ana Ruano, Isidro Jarque, Pilar Galán Alvarez, Carmen Benet Campos, Shally Marcellini-Antonio, Reyes Jimenez-Bárcenas, Daniel Martínez-Carballeira, Dunia de Miguel Llorente, Álvaro Perona Blázquez, Isabel González-Gascón-Y-Marín, Elsa Lopez-Ansoar, José María Alonso Alonso, María Luisa Bengochea-Casado, F J Díaz Gálvez, Ana Moretó, Gemma Moreno, Roberto Hernández-Martin, Erik de Cabo, Julio Davila-Valls, Amalia Cuesta, Carmen Pastoriza Cruz, Gerardo Hermida, Covadonga García, Miguel Angel Pozas-Mañas, Carlos Aguilar-Franco, Dolores Fernandez-Jimenez, Begoña Navas-Elorza, Carolina López-Santamaría Castro, Alvaro Lorenzo Vizcaya, Xavier Ortín, Marta Garcia Pintos, Sonia Piernas, Johana Díaz-Santa, Inmaculada Soto-Ortega, Drew Provan, Gloria García-Donas Gabaldón
Fostamatinib, a recently approved syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here 138 ITP patients (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively. The median age of our cohort (55.8% women) was 66 years (interquartile range, IQR, 56-80 years). The median time since ITP diagnosis at fostamatinib initiation was 51 months (IQR, 10-166 months)...
June 6, 2024: Blood
#2
JOURNAL ARTICLE
Solji Roh, Kohei Hashimoto, Rina Kiriishi, Ken Matsubara, Yuki Isozaki, Hiroaki Tanaka, Tomoyuki Kuwata
The standard treatment for an infected pressure ulcer (PU) with osteomyelitis is debridement, wound coverage and antibiotic administration. However, systemic administration of antibiotics in patients with osteomyelitis is controversial, and the optimal treatment duration for chronic osteomyelitis has not been standardised. We report a case of sudden severe thrombocytopenia induced by piperacillin/tazobactam (PIPC/TAZ) in a patient with PU-related osteomyelitis. A 57-year-old male patient with paraplegia, using a wheelchair full-time, presented to our plastic surgery department with infection of a stage IV hard-to-heal ischial PU...
June 1, 2024: Journal of Wound Care
#3
JOURNAL ARTICLE
Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Xuliang Shen, Jie Jin, Jianmin Luo, Yun Zeng, Xin Zhou, Ruixiang Xia, Zhongxing Jiang, Yuansong Bai, Ting Niu, Renchi Yang, Yu Hu
While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on the switching from eltrombopag to hetrombopag remains scarce. This post-hoc analysis of a phase III hetrombopag trial aimed to assess the outcomes of ITP patients who switched from eltrombopag to hetrombopag. In the original phase III trial, patients initially randomized to the placebo group were switched to eltrombopag. Those who completed this 14-week eltrombopag were eligible to switch to a 24-week hetrombopag...
June 6, 2024: Annals of Hematology
#4
JOURNAL ARTICLE
Tarik Asselah, Vladimir Chulanov, Pietro Lampertico, Heiner Wedemeyer, Adrian Streinu-Cercel, Victor Pântea, Stefan Lazar, Gheorghe Placinta, George S Gherlan, Pavel Bogomolov, Tatyana Stepanova, Viacheslav Morozov, Vladimir Syutkin, Olga Sagalova, Dmitry Manuilov, Renee-Claude Mercier, Lei Ye, Ben L Da, Grace Chee, Audrey H Lau, Anu Osinusi, Marc Bourliere, Vlad Ratziu, Stanislas Pol, Marie-Noëlle Hilleret, Fabien Zoulim
BACKGROUND: In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease. The role of combination therapy with bulevirtide and peginterferon alfa-2a, particularly with regard to finite treatment, is unclear. METHODS: In this phase 2b, open-label trial, we randomly assigned patients to receive peginterferon alfa-2a alone (180 μg per week) for 48 weeks; bulevirtide at a daily dose of 2 mg or 10 mg plus peginterferon alfa-2a (180 μg per week) for 48 weeks, followed by the same daily dose of bulevirtide for 48 weeks; or bulevirtide at a daily dose of 10 mg alone for 96 weeks...
June 6, 2024: New England Journal of Medicine
#5
REVIEW
A B Sugraliyev
The extensive use of therapeutic doses of heparin to prevent thrombosis in critically ill patients with COVID-19 during the pandemic has led to an increased incidence of bleeding and heparin-induced thrombocytopenia (HIT). In addition, the introduction of the AstraZeneca and Johnson&Johnson vaccines against COVID-19 into clinical practice was associated with the development of a rare but very severe, adverse thrombotic complication, vaccine-induced immune thrombotic thrombocytopenia (VITT). Thrombotic complications of VITT turned out to be similar to HIT both clinically and pathophysiologically...
May 31, 2024: Kardiologiia
#6
JOURNAL ARTICLE
Weichen Xiong, Jinwei Chai, Jiena Wu, Jiali Li, Wancheng Lu, Maolin Tian, Mohamed Amine Jmel, Johannes H Ippel, Michail Kotsyfakis, Ingrid Dijkgraaf, Shuwen Liu, Xueqing Xu
Platelet activation contributes to sepsis development, leading to microthrombosis and increased inflammation, which results in disseminated intravascular coagulation and multiple organ dysfunction. Although Cathelicidin can alleviate sepsis, its role in sepsis regulation remains largely unexplored. In this study, we identified Cath-HG, a novel Cathelicidin from Hylarana guentheri skin, and analyzed its structure using nuclear magnetic resonance spectroscopy. The modulatory effect of Cath-HG on the symptoms of mice with sepsis induced by cecal ligation and puncture was evaluated in vivo, and the platelet count, degree of organ damage, and microthrombosis were measured...
2024: Research: a science partner journal
#7
JOURNAL ARTICLE
Kyle L Granger, Trish Paulos, Mary-Keara Boss, Liz Guieu, Sarah Shropshire
In human medicine, hemostatic disorders such as thrombocytopenia, hyperfibrinolysis, and disseminated intravascular coagulopathy (DIC) have been associated with many cancers. Acute hemorrhage secondary to hyperfibrinolysis has been predominantly reported with prostatic adenocarcinoma in human patients. To the author's knowledge, severe bleeding due to paraneoplastic hyperfibrinolysis has not yet been reported in veterinary medicine. The case involves an 8-year-old neutered male Border Collie who was evaluated for progressive and recurrent epistaxis, having a history of 1 year of treatment for metastatic nasal adenocarcinoma...
2024: Frontiers in Veterinary Science
#8
JOURNAL ARTICLE
Carl Thomas Anthon, Frédéric Pène, Anders Perner, Elie Azoulay, Kathryn Puxty, Andry Van De Louw, Sanjay Chawla, Pedro Castro, Pedro Povoa, Luis Coelho, Victoria Metaxa, Matthias Kochanek, Tobias Liebregts, Thomas Kander, Mirka Sivula, Jo Bønding Andreasen, Lene Bjerregaard Nielsen, Christine Lodberg Hvas, Etienne Dufranc, Emmanuel Canet, Christopher John Wright, Julien Schmidt, Fabrice Uhel, Louai Missri, Mette Krag, Elisabet Cos Badia, Cándido Díaz-Lagares, Sophie Menat, Guillaume Voiriot, Niels Erikstrup Clausen, Kristian Lorentzen, Reidar Kvåle, Andreas Barratt-Due, Thomas Hildebrandt, Aleksander Rygh Holten, Kristian Strand, Morten Heiberg Bestle, Pål Klepstad, Damien Vimpere, Carolina Paulino, Catherina Lueck, Christian Svendsen Juhl, Carolina Costa, Per Martin Bådstøløkken, Lia Susana Aires Lêdo, Morten Hylander Møller, Lene Russell
BACKGROUND: Platelet transfusions are frequently used in the intensive care unit (ICU), but current practices including used product types, volumes, doses and effects are unknown. STUDY DESIGN AND METHODS: Sub-study of the inception cohort study 'Thrombocytopenia and Platelet Transfusions in the ICU (PLOT-ICU)', including acutely admitted, adult ICU patients with thrombocytopenia (platelet count <150 × 109 /L). The primary outcome was the number of patients receiving platelet transfusion in ICU by product type...
June 5, 2024: Acta Anaesthesiologica Scandinavica
#9
JOURNAL ARTICLE
Rodrigo Holanda Mendonça, Adriana Banzzatto Ortega, Ciro Matsui, Vanessa van der Linden, Marcelo Kerstenetzky, Luis Fernando Grossklauss, Elizabeth L Silveira-Lucas, Graziela Jorge Polido, Edmar Zanoteli
Spinal muscular atrophy (SMA) is a motor neuron disease associated with progressive muscle weakness, ventilatory failure, and reduced survival. Onasemnogene abeparvovec is the first gene replacement therapy (GT) approved to treat this condition. An observational retrospective study was conducted to assess adverse events and efficacy of GT in SMA patients. Forty-one patients with SMA (58.5% females and 80.1% SMA type 1) were included. The mean age at GT dosing was 18 (±6.4) months. Thirty-six patients (87...
June 5, 2024: Gene Therapy
#10
JOURNAL ARTICLE
Joshua Gardner, Simon Timothy Abrams, Cheng-Hock Toh, Alan L Parker, Charlotte Lovatt, Phillip L R Nicolson, Steve P Watson, Sophie Grice, Luisa Hering, Munir Pirmohamed, Dean J Naisbitt
Vaccination has proven to be a valuable tool to combat SARS-CoV-2. However, reports of rare adverse reactions such as thrombosis/thrombocytopenia syndrome after ChAdOx1 nCoV-19 vaccination have caused scientific, public and media concern. ChAdOx1 was vectorised from the Y25 chimpanzee adenovirus, which was selected due to low human seroprevalence to circumvent pre-existing immunity. In this study, we aimed to explore patterns of T-cell activation after SARS-CoV-2 COVID-19 vaccine exposure in vitro using PBMCs collected from pre-pandemic ChAdOx1 nCoV-19 naïve healthy donors (HDs), and ChAdOx1 nCoV-19 and Pfizer vaccinated controls...
June 5, 2024: NPJ Vaccines
#11
JOURNAL ARTICLE
Shin Nagai, Hiroaki Hiraiwa, Ryota Ito, Yuichiro Koyama, Kiyota Kondo, Shingo Kazama, Toru Kondo, Ryota Morimoto, Takahiro Okumura, Hideki Ito, Tomo Yoshizumi, Masato Mutsuga, Toyoaki Murohara
Percutaneous mechanical circulatory support utilizing micro-axial flow pumps, such as the Impella group of devices, has become a life-saving technique in the treatment of refractory cardiogenic shock, with ever-increasing success rates. A 30-year-old man presented with acute decompensated heart failure and a severely reduced left ventricular ejection fraction (17%). Despite initial treatment with inotropic drugs and intra-aortic balloon pump support, his hemodynamic status remained unstable. Transition to Impella CP mechanical circulatory support was made on day 6 owing to persistently low systolic blood pressure...
June 6, 2024: Journal of Artificial Organs: the Official Journal of the Japanese Society for Artificial Organs
#12
JOURNAL ARTICLE
Laura Lorente Fernández, Samuel Romero Domínguez, Asunción Albert Marí, Esperanza Núñez Benito, Eduardo López Briz, José Luis Poveda Andrés
OBJECTIVE: The primary objective is to describe the real-life effectiveness and safety of nivolumab treatment in patients with relapsed or refractory classical Hodgkin's lymphoma. The secondary objective is to describe the therapeutic management after nivolumab monotherapy. METHOD: Observational, retrospective, multidisciplinary study including all patients with relapsed or refractory classical Hodgkin's lymphoma treated with nivolumab monotherapy from November 2015 to March 2023...
June 4, 2024: Farmacia Hospitalaria
#13
REVIEW
Charlotte A Easton-Jones
Primary immune mediated hemolytic anemia (IMHA) and thrombocytopenia (IMTP) are rare in horses with the conditions more commonly occurring secondary to underlying disease. Several case reports have suggested a link between neoplasia and immune-mediated destruction of platelets and red blood cells. Diagnostic investigations should therefore focus on identifying possible underlying causes such as infections and neoplasia. Immunosuppressive therapy with corticosteroids and azathioprine is the mainstay of treatment but should be used cautiously in cases where underlying infection has not been excluded...
June 4, 2024: Veterinary Clinics of North America. Equine Practice
#14
JOURNAL ARTICLE
Yuzhu Xu, Cuicui Liu, Qi Zhou, Hongqiu Gu, Yanan Jia, Danlin Meng, Jinyang Wang, Wenjun Li, Junyan Liu, Zixiao Li, Xin Yang, Li Guo
BACKGROUND AND OBJECTIVE: Our study aimed to evaluate the associations between platelet count (PC) and in-hospital outcomes for patients with stroke after rt-PA intravenous thrombolysis. METHODS: We identified patients who had been hospitalized with a primary diagnosis of stroke and had received rt-PA intravenous thrombolysis from June 2015 to July 2019 at participating hospitals in the Chinese Stroke Center Alliance. PC measured before intravenous thrombolysis was categorized into the following four groups: severe thrombocytopenia (PC<100 × 109 /L), mild thrombocytopenia (100≤PC<150 × 109 /L), normal PC (150≤PC≤450 × 109 /L), and thrombocythemia (PC>450 × 109 /L)...
June 3, 2024: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
#15
JOURNAL ARTICLE
Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng, Matthew Lee, Sanhita Rath, Harshil Dhruv, Yue Hao, Michael E Berens, Tobias Walbert, Matthias Holdhoff, Glenn J Lesser, Timothy F Cloughesy, Andrew E Sloan, Naoko Takebe, Marta Couce, David M Peereboom, Burt Nabors, Patrick Y Wen, Stuart A Grossman, Lisa R Rogers
PURPOSE: Patients with glioblastoma (GBM) have a dismal prognosis. While DNA alkylating agent temozolomide (TMZ) is mainstay of chemotherapy, therapeutic resistance develops rapidly in patients. Base excision repair inhibitor TRC102 (methoxyamine) reverses TMZ resistance in preclinical glioma models. We sought to investigate efficacy and safety of oral TRC102+TMZ for recurrent GBM (rGBM). PATIENTS AND METHODS: A pre-registered (NCT02395692), non-randomized, multicenter, phase 2 clinical trial (BERT) was planned and conducted through the Adult Brain Tumor Consortium (ABTC-1402)...
June 5, 2024: Clinical Cancer Research
#16
JOURNAL ARTICLE
Ruyi Xie, Huimin Li, Xian Wang, Xiaowei Li
We report a 67-year-old man who presented with poor dietary intake and fatigue. Laboratory tests showed leukopenia, antinuclear antibody (ANA) positivity, anti-dsDNA antibody (A-dsDNA) and anti-Smith antibody (anti-Sm) negativity, decreased C3 and C4, elevated serum immunoglobulin G (IgG), IgG4, and creatinine, and 1.25 g urinary protein at 24 hours. As his condition worsened, re-examination showed thrombocytopenia and A-dsDNA positivity, and renal biopsy pathology showed IgG4-related tubulointerstitial nephritis...
June 5, 2024: Clinical Nephrology
#17
JOURNAL ARTICLE
Gergo Peter Szekeres, Douglas P Dyer, Rebecca L Miller, Kevin Pagel
Heparin, a widely used clinical anticoagulant, is generally well-tolerated; however, approximately 1% of patients develop heparin-induced thrombocytopenia (HIT), a serious side effect. While efforts to understand the role of chemokines in HIT development are ongoing, certain aspects remain less studied, such as the stabilization of chemokine oligomers by heparin. Here, we conducted a combined ion mobility-native mass spectrometry study to investigate the stability of chemokine oligomers and their complexes with fondaparinux, a synthetic heparin analog...
June 5, 2024: Journal of the American Society for Mass Spectrometry
#18
JOURNAL ARTICLE
Magdalena Karasek, Anna Armatys, Marek Skarupski, Łukasz Bołkun, Katarzyna Budziszewska, Joanna Drozd-Sokołowska, Ewa Zarzycka, Patrycja Mensah-Glanowska, Małgorzata Gajewska, Janusz Hałka, Agnieszka Kopacz, Witold Prejzer, Olga Chyrko, Tomasz Wróbel, Agnieszka Wierzbowska, Marta Sobas
INTRODUCTION: Mixed-phenotype acute leukemia (MPAL) is a rare disease with poor prognosis. So far, no standard approach has been established as the "know-how" of MPAL is based only on retrospective analyses performed on small groups of patients. MATERIALS AND METHODS: In this study, a retrospective analysis of the outcomes of adult MPAL patients included in the PALG registry between 2005 and 2024 who received the CLAG-M hybrid protocol as induction or salvage therapy was performed...
2024: Frontiers in Oncology
#19
JOURNAL ARTICLE
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Karen Paula Geboes, Aurélien Lambert, Emmanuel Mitry, Philippe Alexandre Cassier, Jean-Frédéric Blanc, Lorenzo Pilla, Jaime Feliu Batlle, Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid, Inmaculada Gallego, Karin Enell Smith, Peter Ellmark, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Teresa Macarulla
BACKGROUND: Current systemic therapies for metastatic pancreatic ductal adenocarcinoma are associated with poor outcomes with a 5-year overall survival rate under 5%. We aimed to assess the safety and antitumour activity of mitazalimab, a human CD40 agonistic IgG1 antibody, with modified FOLFIRINOX (mFOLFIRINOX; fluorouracil, leucovorin, oxaliplatin, and irinotecan), in chemotherapy-naive patients with metastatic pancreatic ductal adenocarcinoma. METHODS: OPTIMIZE-1 was a single-arm, multicentre, phase 1b/2 study which enrolled adults with histologically-confirmed metastatic pancreatic ductal adenocarcinoma and European Cooperative Oncology Group performance status 0 or 1 in 14 university hospitals in Belgium, France, and Spain...
May 31, 2024: Lancet Oncology
#20
JOURNAL ARTICLE
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, Whitney S Graybill, Ana Beatriz Sánchez, Colleen McCormick, Jean-François Baurain, Anna V Tinker, Hannelore Denys, Roisin E O'Cearbhaill, Sakari Hietanen, Richard G Moore, Anja Ør Knudsen, Thibault de La Motte Rouge, Florian Heitz, Tally Levy, Whitney York, Divya Gupta, Bradley J Monk, Antonio González-Martín
OBJECTIVE: To evaluate the impact of age on the efficacy and safety of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer with a complete/partial response to first-line platinum-based chemotherapy. METHODS: Post hoc analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016). Patients in the intent-to-treat population were categorized according to age at baseline (<65 years vs ≥65 years), and progression-free survival (PFS), safety, and health-related quality of life (HRQOL) were evaluated for each age subgroup (clinical cutoff date, May 17, 2019)...
June 3, 2024: Gynecologic Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
